Intensive Blood-Pressure Control in Patients with Type 2 Diabetes

In this large-scale, multicenter randomized trial across China, 12,821 patients with type 2 diabetes and elevated systolic blood pressure were assigned to either an intensive treatment group (target <120 mm Hg) or a standard treatment group (target <140 mm Hg). Over a median follow-up of 4.2 years, the intensive group had a significantly lower incidence of major cardiovascular events (hazard ratio 0.79), including nonfatal strokes and myocardial infarctions. Serious adverse events were similar across groups, though hypotension and hyperkalemia occurred more frequently in the intensive-treatment group. The findings support a more aggressive systolic blood pressure target to reduce cardiovascular risk in this population.

In this large-scale, multicenter randomized trial across China, 12,821 patients with type 2 diabetes and elevated systolic blood pressure were assigned to either an intensive treatment group (target <120 mm Hg) or a standard treatment group (target <140 mm Hg). Over a median follow-up of 4.2 years, the intensive group had a significantly lower incidence of major cardiovascular events (hazard ratio 0.79), including nonfatal strokes and myocardial infarctions. Serious adverse events were similar across groups, though hypotension and hyperkalemia occurred more frequently in the intensive-treatment group. The findings support a more aggressive systolic blood pressure target to reduce cardiovascular risk in this population.